Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexloxiglumide in gastroesophageal reflux disease
2007-003478-25Phase 2Terminated
- Sponsor
- Rottapharm Biotech
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Dexloxiglumide with Placebo (2 arms). Primary endpoint: Reduction in number of transient lower esophageal sphincter relaxations. Started Mar 2009; status: terminated.
02
Drugs
Dexloxiglumide
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2007-003478-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003478-25.